Marjan Zakeri

Marjan Zakeri


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2024 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
MZMarjan Zakeri
Marjan Zakeri
BFBilqees Fatima
Bilqees Fatima
SYSahar Yazdanfard
Sahar Yazdanfard
SSSujit S Sansgiry
Sujit S Sansgiry

29 July 2025 in Pharmacy
Verified
Journal Article
Open access
PDF file
JKJaveria Khalid
Javeria Khalid
TTTarilate Temedie-Asogwa
Tarilate Temedie-Asogwa
MZMarjan Zakeri
Marjan Zakeri
SSSujit S Sansgiry
Sujit S Sansgiry
Adverse drug reactions (ADRs) significantly affect patient safety and healthcare spending worldwide. Hospital pharmacists are uniquely positioned to address ADRs due to their crucial role in medication management. However, underreporting remains a global concern, especially in developing countries, where pharmacovigilance systems are inadequately developed. Therefore, this pilot study aimed to evaluate and compare the knowledge, attitudes, perceived barriers, and facilitators regarding ADR reporting by hospital pharmacists in a developed (US) and a developing (Pakistan) country. A cross-sectional survey was conducted, using a pre-validated questionnaire. The pharmacists, possessing a minimum of one year’s hospital experience, were selected via convenience sampling. Out of 151 respondents, included in the final analysis (US: n = 51; Pakistan: n = 100), the majority were female (62.3%), aged 29–35 years (38%), and possessed a Pharm. D degree (49.7%). The knowledge (US: 6.03 ± 0.27 vs. Pakistan:5.69 ± 0.25, p-value = 0.193) and attitude scores (US: 32.02 ± 0.73 vs. Pakistan: 32.63 ± 0.67; p-value = 0.379) exhibited no significant differences between the groups. Nonetheless, barriers at both the individual and systemic levels were more pronounced in the developing country. Important facilitators reported were mobile applications for ADR reporting, specialized training, and intuitive reporting tools. In conclusion, we found that pharmacists in both settings exhibit comparable knowledge and positive attitudes towards ADR reporting, though specific contextual barriers are present. Interventions customized to the local hospital infrastructure are crucial for enhancing ADR reporting, particularly in resource-constrained settings.

3 April 2023 in Pediatric Reports
Verified
Journal Article
Open access
PDF file
MZMarjan Zakeri
Marjan Zakeri
EEEkere J. Essien
Ekere J. Essien
SSSujit S Sansgiry
Sujit S Sansgiry
Background: During the COVID-19 pandemic, this study aimed to understand how a mother’s current COVID-19 prevention behaviors were associated with the mother’s future intention to vaccinate their children against COVID-19. Methods: Using a cross-sectional online survey, mothers who had at least one child between 3 and 15 years old were recruited. COVID-19 prevention behaviors evaluated were wearing a mask, appropriate coughing/sneezing, social distancing, staying home, and handwashing. Participants’ age, marital status, race, educational level, incidence of COVID-19 infection in the household, healthcare worker in the household, and future intention to vaccinate children were obtained. Results: Among the 595 participants, 38.3% indicated they did not intend to use the COVID-19 vaccine for their children. Participants with no intention for vaccination had lower mean scores on wearing masks (p < 0.0001), social distancing (p < 0.0001), staying home (p < 0.0001), and handwashing (p < 0.05). The incidence of COVID-19 infection in the household was associated with a lower mean score of staying home (p < 0.01). Conclusion: Our findings indicate that most mothers were compliant with the CDC recommended guidelines at the time of the survey. Mothers who indicated high adherence to prevention behaviors had a higher likelihood to consider vaccination for their children. Now that the COVID-19 vaccine is available for children as young as six months, healthcare providers need to be aware of the relationship between current prevention behaviors and future intention to vaccinate. They need to counsel parents appropriately with recommendations for children to keep practicing prevention behaviors.

16 June 2026 in Cancer Medicine
Verified
Journal Article
Open access
MZMarjan Zakeri
Marjan Zakeri
SWSamuel Wagner
Samuel Wagner
XZXianxin Zhu
Xianxin Zhu
OBOnur Baser
Onur Baser
Background: Mucosal melanoma (MM) is a rare, aggressive disease, often diagnosed late, and associated with poor survival. Surgical resection is the main potential curative option, but anatomical complexity limits feasibility, and real‐world evidence on treatment patterns remains scarce. This study aimed to describe treatment patterns across lines of therapy among patients diagnosed with MM in the US Surveillance, Epidemiology, and End Results Program (SEER)‐Medicare–linked population. Methods: A retrospective analysis was conducted using SEER‐Medicare–linked data from January 2014 through December 2021, with follow‐up through December 2023. Patients aged ≥ 65 years with MM were identified using SEER histology and International Classification of Diseases for Oncology, Third Edition (ICD‐O‐3) topography codes. Treatment patterns were evaluated by categorizing patients into surgical and nonsurgical cohorts and assessing systemic therapy use across lines of treatment. Descriptive statistics summarized patient demographics, tumor characteristics, and treatment modalities. Results: Among 1362 MM patients (median age, 76 years; 57.6% female), 41.3% underwent surgery. Among surgical patients, 36.2% received adjuvant systemic therapy, with PD‐1/PD‐L1–based regimens accounting for 51.5% overall; use varied by primary site and stage, with higher uptake in rectal/anal and nasal cavity melanoma and in regional‐stage disease. In the nonsurgical cohort, 63.3% received systemic therapy as first‐line treatment, with higher use in rectal/anal melanoma and distant‐stage disease. PD‐1/PD‐L1–based regimens predominated (66.6%), with monotherapy used in 55.5% and combination therapy more frequently selected in higher‐risk subsites and advanced‐stage disease. Conclusion: Combination regimens were more common among patients who did not undergo surgery and in certain high‐risk subsites, reflecting heterogeneity in treatment intensity across anatomical locations and stages. This pattern likely reflects more advanced or complex disease presentations in these groups, underscoring the need for intensified therapy despite the higher risk of toxicity.

25 May 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
ALAmy W Law
Amy W Law
DMDanielle Mayer
Danielle Mayer
MZMarjan Zakeri
Marjan Zakeri
NYNehir Yapar
Nehir Yapar
APAlexandra Passarelli
Alexandra Passarelli
PMPia D.M. MacDonald
Pia D.M. MacDonald
Background/Objectives: Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations in the United States. Prevention strategies are recommended to mitigate severe RSV outcomes. In addition to identifying potential coverage gaps, preventative administration timing is important for estimating product effectiveness. This study characterized administration timing of maternal and infant immunization against RSV across the United States during the 2024–2025 RSV season. Methods: A retrospective cross-sectional study was conducted using administrative claims of a commercially insured population from Kythera Labs. Pregnant individuals who received RSVpreF vaccine and infants who received nirsevimab were included. The seasonal cohort included infants born during the RSV season, while infants born from April to September were considered as the catch-up cohort. Baseline characteristics and calendar month and age at immunization (gestational age for RSVpreF) were evaluated. Results: Overall, 37,686 (71.9%) of maternal vaccinations were administered at 32–34 gestational weeks and 92.7% of all vaccinations occurred ≥14 days before delivery. Among infants who received nirsevimab, 34.8% of the seasonal cohort were immunized within 1 week of birth and 33.4% of the catch-up cohort were immunized in October 2024. Conclusions: Most maternal RSVpreF vaccinations occurred early in the recommended eligible gestational age window, while only approximately one-third of infants received nirsevimab during the first week of life or at the beginning of the RSV season. These findings highlight the importance of timely administration of RSV preventives. They further demonstrate that immunization timing should be incorporated into evaluation of the effectiveness and population level impact of RSV prevention programs.